

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

Equality and health inequality impact assessment

**Ciltacabtagene autoleucel for treating relapsed and
lenalidomide-refractory multiple myeloma after 1 to 3
therapies [GID-TA12518]**

Scoping

- 1 Have any potential equality issues been identified during the scoping process? If so, what are they?**

No

- 2 Have any potential health inequality issues been identified during the scoping process? If so, what are they?**

No

- 3 What is the preliminary view as to what extent the committee needs to address the potential issues set out in questions 1 and 2?**

N/A

- 4 Has any change to the draft scope been agreed to highlight the potential equality or health inequality issues set out in questions 1 and 2 following the scope consultation?**

N/A

- 5 Has the stakeholder list been updated as a result of additional equality or health inequality issues identified during the scoping process?**

N/A

Approved by senior responsible officer: Ross Dent, Associate Director

Date: 23/06/2026